The pharmaceutical giant Gilead Sciences Inc. just days ago accused the United States of violating collaboration agreements in a new civil court complaint in Washington that comes as the company is winning praise from the Trump administration for a drug that shows early promise for treating patients suffering from the novel coronavirus.

Gilead’s case in the U.S. Court of Federal Claims, filed by lawyers from Wilmer Cutler Pickering Hale and Dorr, confronts agreements between the United States and Gilead concerning HIV treatment and prevention. The complaint alleged the federal government had asserted “patents that it secretly obtained in violation of the collaboration agreements that Gilead entered into and executed in good faith.”

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]